Sanofi, Blackstone partner to advance multiple myeloma treatment
Under the collaboration, funds managed by Blackstone Life Sciences (BXLS) will provide $329.1m (€300m) to speed up the pivotal studies as well as clinical development programme for a
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
The company’s application for the investigational, oral small molecule potassium-competitive acid blocker vonoprazan is based on the positive results announced earlier from its pivotal Phase III PHALCON-EE trial.